medline.ch Onkologie Urologische Tumoren

	Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China. Urol Oncol Dong Y, Tian Z, Chen W, Li Z, Chen Z, Hu J, Fu B, Xu X, Zhang X, Wang B. PMID: 42772021 [PubMed - as supplied by publisher]
	A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study. PLoS One Wu Y, Li G, Jiang L, Zhang C, Fang H, Fan H. PMID: 42771603 [PubMed - indexed for MEDLINE]
	Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial. Int Urol Nephrol Zaza MM, ElAzab ME, Ebskharoun SF, Salem TAM, Ali MH, Mousa W. PMID: 42771231 [PubMed - as supplied by publisher]
	Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry. Support Care Cancer Solberg A, Grydeland M, Nilsen TS, Storås AH, Davis ID, Greaves N, Anderson S, Fay AP, Chi KN, Enting D, McDermott R, Badal S, Waihenya CG, Popoola A, Lazarus JM, Mateo J, Bjartell A, Omlin A, Odedina F, Ragin C, Mucci LA, Russnes KM, IRONMAN investigators. PMID: 42771055 [PubMed - indexed for MEDLINE]
	[Current diagnostic and treatment practices for different stages of prostate cancer-real-world data from aÂ nationwide survey by the German Society for Immuno- and Targeted Therapy (DGFIT)]. Urologie Hegele A, Doehn C, Varga Z, Wagner U, Noessner E, Hübner A, Heinzer H, Siebels M. PMID: 42771044 [PubMed - as supplied by publisher]
	Theranostics in the management of prostate cancer: from concept to clinical practice. Expert Rev Clin Pharmacol Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM, Fiala O, Rehan F, Mena Cortes D, Santeoni M. PMID: 42770599 [PubMed - as supplied by publisher]
	Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group. Cancer Manag Res Bamias A, Liontos M, Binas I, Stefanou D, Tzannis K, Zakopoulou R, Dedes N, Deligiannis D, Katsiana I, Mamali A, Galari M, Kakogianni K, Nikolaidou V, Ziogas DC, Moulavasilis N, Magoula V, Giannopoulou E, Christodoulou C, Dimopoulos MA, Chrisofos M. PMID: 42770041 [PubMed]
	Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs. Oncol Res Spirito L, Quintavalle C, Coppola P, Esposito M, Esposito F, De Vita G, Pallante P. PMID: 42769902 [PubMed - indexed for MEDLINE]
	Comparison of Neoadjuvant Chemotherapy, Chemoimmunotherapy, and Upfront Radical Cystectomy in High-Risk Bladder Cancer: A Single-Center Retrospective Study. Oncol Res Chen S, Gan X, Lv P, Meng Q, Lin X, Zhang Q. PMID: 42769886 [PubMed - indexed for MEDLINE]
	Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis. Oncol Res Bai Z, Song X, Sun J, Xiao W, Meng X, Dong W. PMID: 42769802 [PubMed - indexed for MEDLINE]
	Immunotherapy in Bellini Duct Carcinoma: A Systematic Review. Oncol Res Lázaro-Sánchez AD, Benítez-Fuentes JD, Wikström-Fernández S, Nevado-Rodríguez M, Conesa-Zamora P, Luengo-Gil G, Ivars-Rubio A, Zafra-Poves M, Carosella ED, Fernández-Molina B, Nieto-Olivares A, Sánchez de Las Matas Garre MJ, Arroyo AB. PMID: 42769789 [PubMed - indexed for MEDLINE]
	Programmed Cell Death in Urological Cancers: Orchestrating the Immune Microenvironment and Immunotherapy. Oncol Res Ye Z, Luo J, Zhang Y, Lu L, Lei M, Deng S. PMID: 42769782 [PubMed - indexed for MEDLINE]
	Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas. Front Immunol Lütje LS, Gruner C, Karsten CM, Merseburger AS, Roesch MC. PMID: 42769490 [PubMed - indexed for MEDLINE]
	Changes in circulating immune cells and cytokines after high-intensity aerobic exercise in patients with prostate cancer undergoing active surveillance from the ERASE randomized controlled trial. Front Immunol Kang DW, Patel D, Field CJ, Boulé NG, Fairey AS, Schadler KL, Courneya KS. PMID: 42769245 [PubMed - indexed for MEDLINE]
	Information and Education Needs in Prostate Cancer Care in Western Guangxi, China: A Single-Center Cross-Sectional Study. J Multidiscip Healthc Cao J, He C, Ji J, Cao N, Peng X, Huang L. PMID: 42769111 [PubMed]
	Long-Term or Recurrent Antibiotic Use During Childhood or Adolescence and the Risk of Kidney Cancer: A Cohort Study. Cancer Med Liu J, Chen X, Jia L, Jing X, Pan X, Zhang X, Jing Z, Yuan J, He Q, Dai X. PMID: 42768754 [PubMed - indexed for MEDLINE]
	Heterotopic prostatic tissue mimicking prostate cancer: the decisive role of multiparametric MRI. BMJ Case Rep Pedde M, Solinas E, Masala S, Scaglione M, Amadu AM. PMID: 42767790 [PubMed - indexed for MEDLINE]
	Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. J Immunother Cancer Zakharia Y, de Spéville BD, Morales-Barrera R, Moreno I, Kilari D, Peguero J, Rao S, Shiue LH, Kanda H, Liu Y, Arora P, Vuppugalla R, Rodriguez-Vida A. PMID: 42767768 [PubMed - indexed for MEDLINE]
	Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genom Cheng N, Ouellette TW, Skead K, Singhawansa A, Elliott M, Cescon DW, Bratman SV, De Carvalho DD, Soave D, Awadalla P. PMID: 42767223 [PubMed - as supplied by publisher]
	Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial. PLoS One Merrick S, South A, Frangou E, Rush HL, Patel G, Thompson J, Plant H, Pickering L, Langley RE, Gilbert DC, Powles T, Larkin J, Meade A. PMID: 42766600 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 181614

Seite 1 von 9081

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung